CompletedNot Applicable

Effective Dose of Statin Post PCI

Iran582 participantsStarted 2020-01-01

Plain-language summary

In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded

Who can participate

Age range52 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * all patients who have undergone PCI due to chronic stable angina Exclusion Criteria: * Patients with acute coronary syndrome * Primary LDL\>190 mg/DL * Patients who developed statin-induced myopathy or rhabdomyolysis * Persistent increase in hepatic enzyme levels or hepatic failure * Pregnancy and breast feeding * Statin hypersensitivity * Patients with history of multiple atherosclerotic events * Patients who received high intensity statin before the study enrollment.

What they're measuring

major adverse cardiovascular events (MACE)

Timeframe: 1 year

serum level of HS-CRP

Timeframe: 1 year

Trial details

NCT IDNCT04923152

SponsorShiraz University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-01-01

View on ClinicalTrials.gov More Statin Dose trials